Evidence map›Paper›PMID 35628208›Full record

ArticleInternational journal of molecular sciences2022

Tumor Promoting Effects of Sulforaphane on Diethylnitrosamine-Induced Murine Hepatocarcinogenesis.

Jie Zheng, Do-Hee Kim, Xizhu Fang, Seong Hoon Kim, Soma Saeidi, Su-Jung Kim, Young-Joon Surh

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jie ZhengCollege of Pharmacy, Seoul National University, Seoul 08826, Korea.
Do-Hee KimDepartment of Chemistry, College of Convergence and Integrated Science, Kyonggi University, Suwon 16627, Korea.
Xizhu FangCollege of Pharmacy, Seoul National University, Seoul 08826, Korea.
Seong Hoon KimCollege of Pharmacy, Seoul National University, Seoul 08826, Korea.ORCID 0000-0002-6573-9071
Soma SaeidiDepartment of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Korea.
Su-Jung KimDepartment of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Korea.ORCID 0000-0002-3636-0644
Young-Joon SurhCollege of Pharmacy, Seoul National University, Seoul 08826, Korea.
Seoul National University · KRKyonggi University · KR

Funding

National Research Foundation of Korea Basic Science Research Grant (2021R1A2C2014186)National Research Foundation of Korea BK21 FOUR Program (5120200513755)
6 · The paper itself

Abstract

Nuclear factor erythroid 2-related factor 2 (NRF2) is a key transcription factor involved in protection against initiation of carcinogenesis in normal cells. Notably, recent studies have demonstrated that aberrant activation of NRF2 accelerates the proliferation and progression of cancer cells. The differential effects of NRF2 on multi-stage carcinogenesis have raised a concern about the validity of NRF2 activators for chemoprevention. This prompted us to assess the effects of sulforaphane (SFN), a prototypic NRF2 activating chemopreventive phytochemical, on experimentally induced carcinogenesis. In the present study, SFN was daily injected intraperitoneally (25 mg/kg) for 3 months to male C57BL/6 mice at 6 months after single intraperitoneal administration of a hepatocarcinogen, diethylnitrosamine (DEN). The liver to body weight ratio, tumor growth, and the number and the size of hepatomas measured at 9 months after DEN administration were significantly higher in SFN-treated mice than those in vehicle-treated mice. Moreover, the expression of NRF2, its target protein NAD(P)H:quinone oxidoreductase 1, and the cell proliferation marker, proliferating cell nuclear antigen was further elevated in DEN plus SFN-treated mice. These results suggest that once hepatocarcinogenesis is initiated, SFN may stimulate tumor progression.

Indexed as

DiethylnitrosamineNF-E2-Related Factor 2AnimalsCarcinogenesisIsothiocyanatesMaleMiceMice, Inbred C57BLSulfoxidesDiethylnitrosamineIsothiocyanatesNF-E2-Related Factor 2sulforaphaneSulfoxideschemopreventiondiethylnitrosaminehepatocellular carcinomaNRF2sulforaphane

Identifiers

PMID35628208
PMCPMC9141104
OpenAlexW4280506714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.